How does hair drug testing work?
Hair drug testing detects analytes incorporated into the hair shaft as it grows from the follicle. A standard 1.5-inch sample cut close to the scalp offers approximately a 90-day lookback, with a roughly 7–10 day delay between use and detectable incorporation. Hair is not federally approved under SAMHSA Mandatory Guidelines or DOT 49 CFR Part 40, and documented melanin-binding affinity raises bias concerns that affect how results should be interpreted.
How hair testing works
Drugs in the bloodstream are incorporated into hair follicles and then into the hair shaft. The closer the sample is taken to the scalp, the more recent the use being tested. With an average hair-growth rate of ~1 cm per month, a standard 1.5-inch (~3.8 cm) sample covers approximately 90 days of growth.
Hair samples are washed at the laboratory to remove external contamination, then digested to release the analytes, which are quantified by mass spectrometry. Hair testing is typically used to detect THC-COOH, cocaine, opioids (including 6-AM for heroin), amphetamines, methamphetamine, PCP, and sometimes EtG (alcohol metabolite).
The 7–10 day incorporation delay
Because hair takes time to grow out from the follicle, drugs used within the last week are not yet detectable in a hair sample. This means a hair test cannot detect very recent use — only historical use across the roughly 7-to-90-day window.
Why hair isn't federally approved
As of 2026, hair specimens are not authorized under SAMHSA Mandatory Guidelines or DOT 49 CFR Part 40 for federally regulated workplace drug testing programs. SAMHSA has been considering hair testing for years but has not finalized Mandatory Guidelines for the specimen type, citing reliability and interpretive concerns.
Practical implication: employers regulated under DOT cannot use hair testing for their regulated workforce. Private-sector non-DOT employers may use hair testing, but should understand that it does not carry the federal regulatory imprimatur of urine.
Documented bias concerns
Published research has documented that certain drug analytes — notably cocaine and methamphetamine — bind more strongly to melanin-rich (darker) hair than to melanin-poor (lighter) hair. This means two people with identical drug exposure can produce meaningfully different hair-test results based on hair color.
Several U.S. court rulings and arbitration decisions have addressed this concern in the context of public-safety employment (notably municipal police hiring). Defensible programs that use hair as a primary screen typically corroborate findings with a second specimen (urine or oral fluid) for any safety- or employment-consequential decision.
External contamination
Hair can pick up drug analytes from environmental exposure (smoke, surfaces, handling) without ingestion. Laboratory wash protocols are designed to remove most surface contamination, but interpretation should account for the possibility — particularly for cocaine and methamphetamine in occupational settings where exposure is plausible.
At a glance: pros and cons
Pros
- Long detection window (~90 days)
- Difficult to evade through short-term abstinence
- Useful for confirming historical patterns
Limits
- Not federally approved (SAMHSA / DOT)
- ~7–10 day incorporation delay — cannot detect recent use
- Documented bias concerns with melanin binding
- External contamination considerations
- Higher cost than urine or oral fluid
Frequently asked questions
A standard 1.5-inch hair sample provides roughly a 90-day lookback, after a ~7–10 day incorporation delay before drug use appears in detectable hair.
No. As of 2026, hair specimens are not authorized under SAMHSA Mandatory Guidelines or 49 CFR Part 40 for federal workplace programs.
Some studies suggest darker hair binds certain drug analytes more strongly than lighter hair due to melanin affinity, raising concerns about potential bias in interpretation. Defensible programs typically corroborate findings with another specimen.
Sources & references
drugtest.co content is sourced from primary regulatory and clinical references. We do not cite gray-market or "how to pass" sources.